Key result
Benidipine significantly reduced the augmentation index from 85.7% to 81.4% in hypertensive patients with chronic kidney disease, though the difference compared to amlodipine was not statistically significant.
Why the study?
Does benidipine improve augmentation index and urinary albumin excretion compared to amlodipine in hypertensive patients with chronic kidney disease?
RCT (n=108)
Open-label
Dynamic allocation procedure based on the minimization method
No
Does benidipine improve augmentation index and urinary albumin excretion compared to amlodipine in hypertensive patients with chronic kidney disease?
Absolute Event Rate: 81.4% vs 84.3%
In hypertensive patients with chronic kidney disease, switching to the T/L-type calcium channel blocker benidipine may improve arterial stiffness and reduce albuminuria in advanced cases compared to the L-type blocker amlodipine.
No takes yet. Share an insight, caveat, or question.
Benidipine was associated with AI improvement in CKD without renal function change; this cohort finding leaves open any preference over amlodipine pending RCTs.
Takayama et al. (2016) conducted an RCT in Hypertension with chronic kidney disease (n=108). Benidipine vs. Amlodipine (2.5-10 mg/day) was evaluated on Augmentation index (AI). Benidipine significantly reduced the augmentation index from 85.7% to 81.4% in hypertensive patients with chronic kidney disease, though the difference compared to amlodipine was not statistically significant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: